IASO BIOMED

They are a developmental stage biotechnology company primarily focused on developing and commercializing an orally delivered proprietary peptide to treat hypogonadism (low testosterone). Their goal is to recover testosterone levels safely and effectively for patients with low testosterone. They have established a collaboration with the Research Institute of the McGill University Health Centre (RIMUHC), a world class facility located in Montreal, where current research and development activities are being conducted. The research team is led by Dr. Vassilios Papadopoulos, one of their founders and directors, who specializes in the biochemist